Multilineage cells from human adipose tissue: Implications for cell-based therapies

Citation
Pa. Zuk et al., Multilineage cells from human adipose tissue: Implications for cell-based therapies, TISSUE ENG, 7(2), 2001, pp. 211-228
Citations number
92
Categorie Soggetti
Cell & Developmental Biology
Journal title
TISSUE ENGINEERING
ISSN journal
10763279 → ACNP
Volume
7
Issue
2
Year of publication
2001
Pages
211 - 228
Database
ISI
SICI code
1076-3279(200104)7:2<211:MCFHAT>2.0.ZU;2-6
Abstract
Future cell-based therapies such as tissue engineering will benefit from a source of autologous pluripotent stem cells. For mesodermal tissue engineer ing, one such source of cells is the bone marrow stroma. The bone marrow co mpartment contains several cell populations, including mesenchymal stem cel ls (MSCs) that are capable of differentiating into adipogenic, osteogenic, chondrogenic, and myogenic cells. However, autologous bone marrow procureme nt has potential limitations. An alternate source of autologous adult stem cells that is obtainable in large quantities, under local anesthesia, with minimal discomfort would be advantageous. In this study, we determined if a population of stem cells could be isolated from human adipose tissue. Huma n adipose tissue, obtained by suction-assisted lipectomy (i.e., liposuction ), was processed to obtain a fibroblast-like population of cells or a proce ssed lipoaspirate (PLA). These PLA cells can be maintained in vitro for ext ended periods with stable population doubling and low levels of senescence. Immunofluorescence and flow cytometry show that the majority of PLA cells are of mesodermal or mesenchymal origin with low levels of contaminating pe ricytes, endothelial cells, and smooth muscle cells. Finally, PLA cells dif ferentiate in vitro into adipogenic, chondrogenic, myogenic, and osteogenic cells in the presence of lineage-specific induction factors. In conclusion , the data support the hypothesis that a human lipoaspirate contains multip otent cells and may represent an alternative stem cell source to bone marro w-derived MSCs.